Skip to main content
Premium Trial:

Request an Annual Quote

Linguamatics Announces $10M in 2013 Sales

Premium

Linguamatics said this week that it exceeded $10 million in sales last year outperforming both growth and sales expectations.

The company said in a statement that its increased sales came from a "boost in new customers and increased software licenses to existing customers in the pharmaceutical and healthcare sectors." This included 130 percent growth in healthcare sales plus increased sales in professional services, Linguamatics said.

Linguamatics developed and sells I2E, a software platform that uses natural language processing to identify and extract information from unstructured text such as scientific literature, patents, clinical trials data, electronic health records, news feeds, social media, and proprietary content and put it into a structured format for further analysis.

The company's customer base includes pharmaceutical companies, the US Food and Drug Administration, hospitals, cancer institutes, and academic research centers.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.